Pan-cancer analysis of super-enhancer-induced LINC00862 and validation as a SIRT1-promoting factor in cervical cancer and gastric cancer

Liu, Shaojun; Wang, Zhaohui; Hu, Lei; Ye, Chao; Zhang, Xubin; Zhu, Zhiqiang; Li, Jiaqiu; Shen, Qi

doi:10.1016/j.tranon.2024.101982

Cited by 2 publications

(2 citation statements)

References 70 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cause of LINC00862 overexpression in gastric and cervical cancer is superenhancer activity. LINC00862 may be a prognostic and diagnostic biomarker [ 51 ]. Age, stage, and risk score were found to be independent predictive markers for patients with GC according to multivariate Cox analysis.…”

Section: Immunological Factorsmentioning

confidence: 99%

“…-FCGR3A-type and CD14-type macrophages were identified using single-cell data to help predict the prognosis and response to immunotherapy in patients with STAD [50] -LINC00862 may be a prognostic and diagnostic biomarker [51] patients with lower risk scores for both PD-1+ and cytotoxic T lymphocyte antigen4+ showed greater sensitivity to immunotherapy [52] the prediction signature of the pathomics-driven ensemble model continued to be an independent predictor for progression-free survival in patients with GC who underwent immunotherapy [53] -GCIPS is an independent predictive factor for both PFS and OS [54]…”

Section: Immunological Predictive Factors Of Immunotherapy In Gastric...mentioning

confidence: 99%

See 1 more Smart Citation

Predictive Factors of Immunotherapy in Gastric Cancer: A 2024 Update

Bintintan,

Burz,

Pintea

et al. 2024

Diagnostics

View full text Add to dashboard Cite

Many studies on gastric cancer treatment have identified predictors of immunotherapy benefits. This article provides an update on the major developments in research related to predictive factors of immunotherapy for gastric cancer. We used the search term “predictive factors, immunotherapy, gastric cancer” to find the most current publications in the PubMed database related to predictive factors of immunotherapy in gastric cancer. Programmed cell death, genetic, and immunological factors are the main study topics of immunotherapy’s predictive factors in gastric cancer. Other preventive factors for immunotherapy in gastric cancer were also found, including clinical factors, tumor microenvironment factors, imaging factors, and extracellular factors. Since there is currently no effective treatment for gastric cancer, we strongly propose that these studies be prioritized.

show abstract

Section: Immunological Factorsmentioning

confidence: 99%

Section: Immunological Predictive Factors Of Immunotherapy In Gastric...mentioning

confidence: 99%

Predictive Factors of Immunotherapy in Gastric Cancer: A 2024 Update

Bintintan,

Burz,

Pintea

et al. 2024

Diagnostics

View full text Add to dashboard Cite

show abstract

The role of SIRT1 in autophagy and drug resistance: unveiling new targets and potential biomarkers in cancer therapy

Tang,

Ju,

Liu

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Cancer, the world’s second leading cause of death after cardiovascular diseases, is characterized by hallmarks such as uncontrolled cell growth, metastasis, angiogenesis, hypoxia, and resistance to therapy. Autophagy, a cellular process that can both support and inhibit cancer progression, plays a critical role in cancer development and progression. This process involves the formation of autophagosomes that ultimately fuse with lysosomes to degrade cellular components. A key regulator of this process is Sirtuin 1 (SIRT1), which significantly influences autophagy. This review delves into the role of SIRT1 in modulating autophagy and its broader impacts on carcinogenesis. SIRT1 regulates crucial autophagy mediators, such as AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR), effectively promoting or suppressing autophagy. Beyond its direct effects on autophagy, SIRT1’s regulatory actions extend to other cell death processes, including apoptosis and ferroptosis, thereby influencing tumor cell proliferation, metastasis, and chemotherapy responses. These insights underscore the complex interplay between SIRT1 and autophagy, with significant implications for cancer therapy. Targeting SIRT1 and its associated pathways presents a promising strategy to manipulate autophagy in cancer treatment. This review underscores the potential of SIRT1 as a therapeutic target, opening new avenues for enhancing cancer treatment efficacy.

show abstract

Pan-cancer analysis of super-enhancer-induced LINC00862 and validation as a SIRT1-promoting factor in cervical cancer and gastric cancer

Cited by 2 publications

References 70 publications

Predictive Factors of Immunotherapy in Gastric Cancer: A 2024 Update

Predictive Factors of Immunotherapy in Gastric Cancer: A 2024 Update

The role of SIRT1 in autophagy and drug resistance: unveiling new targets and potential biomarkers in cancer therapy

Contact Info

Product

Resources

About